HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 X64_SR12 18JUN21:06:47:2118JUN21:06:47:21 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS TV SASDATA 9.4 X64_SR12 18JUN21:06:47:2118JUN21:06:47:21 Trial Visits HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000000800000000000000000000 STUDYID Study Identifier DOMAIN Domain Abbreviation VISITNUMVisit Number "VISIT Visit Name VISITDY Planned Study Day of Visit :ARMCD Planned Arm Code BÇTVSTRL Visit Start Rule I[TVENRL Visit End Rule HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 mRNA-1273-P201TVPrevious Screening  Day of previous inform consent Screen failure mRNA-1273-P201TVAScreening  Start of Screening Epoch End of Screening Epoch mRNA-1273-P201TVA Visit 1 Day 1 A First day of first study vaccination in Part A mRNA-1273-P201TVA0Visit 2 Day 8 A€ 7 (+3) days after first study vaccination in Part A mRNA-1273-P201TVA@Visit 3 Day 15 Ağ 14 (+/-3) days after first study vaccination in Part A mRNA-1273-P201TVAPVisit 4 Day 29 B First day of second study vaccination in Part A mRNA-1273-P201TVA`Visit 5 Day 36 B$ 7 (+3) days after second study vaccination in Part A mRNA-1273-P201TVApVisit 6 Day 43 B+ 14 (+/-3) days after second study vaccination in Part A mRNA-1273-P201TVA€Visit 7 Day 57 B9 28 (+7/-3) days after second study vaccination in Part A mRNA-1273-P201TVASafety Call Day 85 BU 56 (+/-3) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVA Safety Call Day 113 Bq 84 (+/-3) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVA°Safety Call Day 141 B 112 (+/-3) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVAÀSafety Call Day 169 B© 140 (+/-3) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVAĞSafety Call Day 197 BÅ 168 (+/-3) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVAàVisit 8 Day 209 BÑ 180 (+/-14) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVAğSafety Call Day 237 Bí 208 (+/-3) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVBSafety Call Day 265 C 236 (+/-3) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVBSafety Call Day 293 CP 264 (+/-3) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVBSafety Call Day 321 C 292 (+/-3) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVBSafety Call Day 349 CĞ 320 (+/-3) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVBSafety Call Day 377 C 348 (+/-3) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVBVisit 9 Day 394 C  365 (+/-14) days after second study vaccination in Part A and before Participant Decision Visit mRNA-1273-P201TVBParticipant Decision Visit / OL-D1. Start of Part B or Part C mRNA-1273-P201TVBOL-D8 . 7 (+3) days after first study vaccination in Part B or Part C mRNA-1273-P201TVBOL-D15 . 14 (+/-3) days after first study vaccination in Part B or Part C mRNA-1273-P201TVBOL-D29 . First day of second study vaccination in Part B, or 28 (+7) days after first study vaccination in Part B or Part C for subjects receiving only one OL dose mRNA-1273-P201TVBSafety Call OL-D36 . 7 (+3) days after 2nd study vaccination in Part B for subjects receiving 2 OL doses, or 35 (+3) days after 1st study vaccination in Part B or Part C for subjects receiving only one OL dose or no dose mRNA-1273-P201TVBOL-D57 . 28 (+/-3) days after second vaccination in Part B for subjects receiving 2 OL doses, or 56 (+/-3) days after first study vaccination in Part B or Part C for subjects receiving only one OL dose mRNA-1273-P201TVBSafety Call OL-D85 . 56 (+/-3) days after second vaccination in Part B for subjects receiving 2 OL doses, or 84 (+/-3) days after first study vaccination in Part Bor Part C for subjects receiving only one OL dose mRNA-1273-P201TVBSafety Call OL-D113 . 84 (+/-3) days after second vaccination in Part B for subjects receiving 2 OL doses, or 112 (+/-3) days after first study vaccination in Part B or Part C for subjects receiving only one OL dose mRNA-1273-P201TVBSafety Call OL-D141 . 112 (+/-3) days after second vaccination in Part B for subjects receiving 2 OL doses, or 140 (+/-3) days after first study vaccination in Part Bor Part C for subjects receiving only one OL dose mRNA-1273-P201TVBSafety Call OL-D169 . 140 (+/-3) days after second vaccination in Part B for subjects receiving 2 OL doses, or 168 (+/-3) days after first study vaccination in Part B or Part C for subjects receiving only one OL dose mRNA-1273-P201TVB OL-D181 . 180 (+/-14) days after first study vaccination in Part B for subjects receiving only one dose in Part B or Part C, or 180 (+/-14) days after PDV for subjects not receiving dose in Part B End of study for subjects receiving only one dose, or subjects not receiving dose in Part BmRNA-1273-P201TVB!OL-D209 . 180 (+/-14) days after second study vaccination in Part B for subjects receiving 2 OL doses End of study